Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.58 |
| ▸ | CDK2 | P24941 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6893510 | 1.00 | CDK1 (0.59) | CDK1CDK5CDK5R1KDM4ECDK2 | |
| SCHEMBL6893517 | 0.77 | CDK5 (0.47) | CDK1CDK5CDK5R1KDM4ECDK2 | |
| SCHEMBL1918665 | 0.76 | CDK2 (0.56) | CDK1CDK5CDK5R1CDK2MAPT | |
| SCHEMBL6885247 | 0.74 | SRC (0.48) | KDM4EMAPTMAPK1MEN1CYP1A2 | |
| Purvalanola SCHEMBL3311119 | 0.74 | CDK5 (1.00) | CDK1CDK5CDK5R1KDM4ECDK2 | |
| SCHEMBL3445128 | 0.74 | CDK1 (0.72) | CDK1CDK5CDK5R1KDM4ECDK2 | |
| SCHEMBL1918958 | 0.74 | CDK2 (0.58) | CDK1CDK5CDK5R1CDK2CCNA2 | |
| SCHEMBL3445316 | 0.74 | CDK1 (0.72) | CDK1CDK5CDK5R1KDM4ECDK2 | |
| Purvalanola SCHEMBL29360281 | 0.74 | CDK5 (1.00) | CDK1CDK5CDK5R1KDM4ECDK2 | |
| Purvalanola SCHEMBL30375366 | 0.74 | CDK5 (1.00) | CDK1CDK5CDK5R1KDM4ECDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-03-11 | — | — | US | claimed |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-15 | — | — | US | disclosed |
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | CDK1, CDK3, CDKL3 | CDK1 1/4885CDK5 37/4885CDK5R1 51/4885 |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | DTYMK, DGKG, DGKZ | CDK1 925/4885CDK5 988/4885CDK5R1 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.